Migraine deal a headache for Retrophin's Transcept quest?
This article was originally published in Scrip
Executive Summary
In a move that shifts the sands under Retrophin's hostile buyout bid for Transcept Pharmaceuticals, Transept has acquired global rights to a preclinical candidate for acute migraine using novel delivery technology developed by Japan's Shin Nippon Biomedical Laboratories (SNBL).